Surgery News - September 2008 - (Page 16) Expanded broad-spectrum coverage is on your side * 1† * The clinical significance of in vitro activity is unknown. † TYGACIL does not cover Pseudomonas aeruginosa. TYGACIL is indicated for • The treatment of adults with complicated skin and skin structure infections caused by E. coli, E. faecalis (vancomycin-susceptible isolates only), S. aureus (methicillin-susceptible and -resistant isolates), S. agalactiae, S. anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), S. pyogenes, and B. fragilis • The treatment of adults with complicated intra-abdominal infections caused by C. freundii, E. cloacae, E. coli, K. oxytoca, K. pneumoniae, E. faecalis (vancomycin-susceptible isolates only), S. aureus (methicillin-susceptible isolates only), S. anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), B. fragilis, B. thetaiotaomicron, B. uniformis, B. vulgatus, C. perfringens, and P. micros Important Safety Information • To reduce the development of drug-resistant bacteria and maintain the effectiveness of TYGACIL and other antibacterial drugs, TYGACIL should be used only to treat infections proven or strongly suspected to be caused by susceptible bacteria • Anaphylaxis/anaphylactoid reactions have been reported with nearly all antibacterial agents, including tigecycline, and may be life-threatening • TYGACIL is contraindicated in patients with known hypersensitivity to tigecycline • TYGACIL should be administered with caution in patients with known hypersensitivity to tetracycline class antibiotics • Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics and may have similar adverse effects. Such effects may include: photosensitivity, pseudotumor cerebri, and anti-anabolic action (which has led to increased BUN, azotemia, acidosis, and hyperphosphatemia). As with tetracyclines, pancreatitis has been reported with the use of TYGACIL • The safety and efficacy of TYGACIL in patients with hospital-acquired pneumonia have not been established • In clinical trials, the most common treatment-emergent adverse events in patients treated with TYGACIL were nausea (29.5%) and vomiting (19.7%) • TYGACIL may cause fetal harm when administered to a pregnant woman • The safety and effectiveness of TYGACIL in patients below age 18 and lactating women have not been established • Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including TYGACIL, and may range in severity from mild diarrhea to fatal colitis • The use of TYGACIL during tooth development may cause permanent discoloration of the teeth. TYGACIL should not be used during tooth development unless other drugs are not likely to be effective or are contraindicated Please see brief summary of Prescribing Information on adjacent page. Reference: 1. TYGACIL® (tigecycline) Prescribing Information, Wyeth Pharmaceuticals Inc. © 2008, Wyeth Pharmaceuticals Inc., Philadelphia, PA 19101 August 2008 234909-01 Expanded coverage for resistant pathogens
Table of Contents Feed for the Digital Edition of Surgery News - September 2008 Surgery News - September 2008 Contents Appreciation Low Scores News From the College: New Leader Practice Trends: High Price to Pay Surgery News - September 2008 Surgery News - September 2008 - Contents (Page 1) Surgery News - September 2008 - Contents (Page 2) Surgery News - September 2008 - Contents (Page 3) Surgery News - September 2008 - Appreciation (Page 4) Surgery News - September 2008 - Low Scores (Page 5) Surgery News - September 2008 - Low Scores (Page 6) Surgery News - September 2008 - Low Scores (Page 7) Surgery News - September 2008 - News From the College: New Leader (Page 8) Surgery News - September 2008 - News From the College: New Leader (Page 9) Surgery News - September 2008 - News From the College: New Leader (Page 10) Surgery News - September 2008 - Practice Trends: High Price to Pay (Page 11) Surgery News - September 2008 - Practice Trends: High Price to Pay (Page 12) Surgery News - September 2008 - Practice Trends: High Price to Pay (Page 13) Surgery News - September 2008 - Practice Trends: High Price to Pay (Page 14) Surgery News - September 2008 - Practice Trends: High Price to Pay (Page 15) Surgery News - September 2008 - Practice Trends: High Price to Pay (Page 16)
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.